Biglycan, a prominent member of the small leucine-rich proteoglycan (SLRP) family, serves as a crucial mediator in various physiological and pathological processes within the extracellular matrix (ECM). This multifunctional protein is abundantly found in connective tissues, such as cartilage, bone, and blood vessels, where it contributes significantly to the structural integrity and organization of the ECM. Beyond its structural role, Biglycan exerts regulatory functions by interacting with a diverse array of ECM components, cell surface receptors, and signaling molecules. Through these interactions, Biglycan modulates cellular processes including adhesion, migration, proliferation, and inflammation.
Activation of Biglycan involves intricate signaling mechanisms that integrate extracellular cues with intracellular responses. Various pathways contribute to the activation of Biglycan, encompassing both receptor-mediated and intracellular signaling cascades. Receptor-mediated activation occurs through binding of growth factors, such as transforming growth factor-beta (TGF-β) and insulin-like growth factor-1 (IGF-1), to their respective receptors, leading to downstream signaling events that ultimately culminate in the activation of Biglycan. Additionally, Biglycan activation can be induced through intracellular pathways, including cyclic adenosine monophosphate (cAMP)-dependent protein kinase A (PKA) signaling and phosphoinositide 3-kinase (PI3K)/Akt pathway activation. These pathways converge on Biglycan, phosphorylating and modulating its activity to orchestrate ECM remodeling and cellular responses in various physiological contexts.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin activates Biglycan by stimulating adenylate cyclase, leading to increased levels of intracellular cyclic adenosine monophosphate (cAMP) which activates PKA. PKA then phosphorylates and activates Biglycan, promoting its function. | ||||||
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $76.00 $82.00 $367.00 | 36 | |
Dexamethasone activates Biglycan by binding to glucocorticoid receptors, which then translocate to the nucleus and act as transcription factors. This results in increased transcription of Biglycan mRNA, leading to elevated levels of Biglycan protein. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $65.00 $319.00 $575.00 $998.00 | 28 | |
Retinoic Acid activates Biglycan through retinoic acid receptors (RARs), which bind to retinoic acid response elements (RAREs) in the promoter region of the Biglycan gene, enhancing its transcription and subsequent protein expression. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $162.00 $316.00 $559.00 $889.00 $1693.00 | 7 | |
Sphingosine-1-phosphate activates Biglycan through the S1P receptor, which activates downstream signaling pathways including the PI3K/Akt pathway. Activation of Akt leads to the phosphorylation and activation of Biglycan, enhancing its function. | ||||||
Angiotensin II, Human | 4474-91-3 | sc-363643 sc-363643A sc-363643B sc-363643C | 1 mg 5 mg 25 mg 100 mg | $50.00 $75.00 $260.00 $505.00 | 3 | |
Angiotensin II activates Biglycan by binding to its receptor and initiating intracellular signaling pathways such as the MAPK pathway. Activation of this pathway leads to the phosphorylation and activation of transcription factors that regulate Biglycan expression. | ||||||
Angiotensin fragment 1-7 acetate salt | 51833-78-4 | sc-319824 | 1 mg | $82.00 | 1 | |
Angiotensin-(1-7) activates Biglycan by binding to its receptor and initiating intracellular signaling pathways such as the PI3K/Akt pathway. Activation of this pathway leads to the phosphorylation and activation of Biglycan, enhancing its function. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $60.00 $185.00 $365.00 | 64 | |
Resveratrol activates Biglycan by activating the SIRT1 pathway. Resveratrol binds to and activates SIRT1, which then deacetylates and activates transcription factors that regulate Biglycan expression, leading to increased Biglycan levels. | ||||||